James Hayden
Family Medicine · Huntingdon, PANPI 1578697785
Payments from drug & device makers
Across 130 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$282
- AbbVie$253
- Novo Nordisk$246
- Lilly USA, LLC$200
- AstraZeneca$111
- Merck$98
- plus $839 from 18 others
What the payments were for
- Food & beverage$2,028100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 26 | $282 |
| AbbVie(2 entities) | 12 | $253 |
| Novo Nordisk | 15 | $246 |
| Lilly USA, LLC | 14 | $200 |
| AstraZeneca | 7 | $111 |
| Merck | 6 | $98 |
| Pfizer | 6 | $98 |
| Astellas Pharma US Inc | 5 | $93 |
| Johnson & Johnson | 6 | $92 |
| Otsuka America Pharmaceutical, Inc. | 5 | $88 |
| Xeris Pharmaceuticals, Inc. | 3 | $72 |
| Amarin Pharma, Inc. | 4 | $71 |
| Exact Sciences | 4 | $69 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $57 |
| Boehringer Ingelheim | 3 | $37 |
| Novartis | 2 | $34 |
| Philips North America LLC | 2 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Biogen | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Abbott | 1 | $13 |
How this compares
$2,028 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 20 | $24,827 |
| TrulicityDulaglutide | 14 | $23,046 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $20,476 |
| OzempicSemaglutide | 14 | $20,328 |
| EliquisApixaban | 15 | $20,186 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $10,219 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $2,920 |
| Pantoprazole Sodium | 76 | $1,666 |
| SynthroidLevothyroxine Sodium | 17 | $1,379 |
| Lisinopril | 137 | $1,357 |
| Famotidine | 47 | $1,197 |
| Ezetimibe | 39 | $1,167 |
| Atorvastatin Calcium | 102 | $1,157 |
| Simvastatin | 72 | $772 |
| Mometasone Furoate | 14 | $752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $282 | $30,69544 claims |
| Boehringer IngelheimJardiance | $37 | $24,82720 claims |
| Lilly USA, LLCTrulicity | $200 | $23,04614 claims |
| Novo NordiskOzempic | $246 | $20,32814 claims |
| PfizerEliquis | $98 | $20,18615 claims |
| AbbVieSynthroid | $253 | $1,37917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Huntingdon
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.